Neural and immune mechanisms in the pathogenesis of Parkinson's disease.
about
Immunotherapy in Parkinson's Disease: Micromanaging Alpha-Synuclein AggregationMethod designed to respect molecular heterogeneity can profoundly correct present data interpretations for genome-wide expression analysisInfluence of Estrogen Modulation on Glia Activation in a Murine Model of Parkinson's DiseaseModeling nigrostriatal degeneration in organotypic cultures, a new ex vivo model of Parkinson's diseaseNeuronal cellular responses to extremely low frequency electromagnetic field exposure: implications regarding oxidative stress and neurodegenerationLipolysaccharide-Induced Neuroinflammation Is Associated with Alzheimer-Like Amyloidogenic Axonal Pathology and Dendritic Degeneration in Rats.The role of Galectin-3 in α-synuclein-induced microglial activation.Transient transfection of human CDNF gene reduces the 6-hydroxydopamine-induced neuroinflammation in the rat substantia nigraActivation of GSK-3β and caspase-3 occurs in Nigral dopamine neurons during the development of apoptosis activated by a striatal injection of 6-hydroxydopamineA novel compound VSC2 has anti-inflammatory and antioxidant properties in microglia and in Parkinson's disease animal model.Fractalkine over expression suppresses α-synuclein-mediated neurodegenerationLithium protects against paraquat neurotoxicity by NRF2 activation and miR-34a inhibition in SH-SY5Y cells.Involvement of bone marrow cells and neuroinflammation in hypertension.Microglial M1/M2 polarization and metabolic states.LPS-induced Murine Neuroinflammation Model: Main Features and Suitability for Pre-clinical Assessment of NutraceuticalsCentral CB2 receptors in inflammation-driven neurodegeneration: dysregulation and therapeutic potentialDopamine receptor agonists for Parkinson's disease.Targeting α-synuclein as a therapeutic strategy for Parkinson's disease.Current and investigational non-dopaminergic agents for management of motor symptoms (including motor complications) in Parkinson's disease.Targeting specific cells in the brain with nanomedicines for CNS therapiesClinical drug research in chronic central neurodegenerative disorders.Estrogens, Neuroinflammation, and Neurodegeneration.Complex Changes in the Innate and Adaptive Immunity Accompany Progressive Degeneration of the Nigrostriatal Pathway Induced by Intrastriatal Injection of 6-Hydroxydopamine in the Rat.Warburg effect linked to cognitive-executive deficits in FMR1 premutation.Neuroprotective effect of pseudoginsenoside-f11 on a rat model of Parkinson's disease induced by 6-hydroxydopamine.Is the Enzyme ACMSD a Novel Therapeutic Target in Parkinson's Disease?The first Insubria autumn school on neuroimmunopharmacology: challenging paradigms beyond boundaries.Triggering Receptor Expressed on Myeloid Cells 2 Overexpression Inhibits Proinflammatory Cytokines in Lipopolysaccharide-Stimulated Microglia.The Second Insubria Autumn School on Neuroimmune Pharmacology: Repurposing Established Drugs for Novel Indications.Downregulation of DEC1 contributes to the neurotoxicity induced by MPP+ by suppressing PI3K/Akt/GSK3β pathway.Vitamin D Treatment Attenuates Neuroinflammation and Dopaminergic Neurodegeneration in an Animal Model of Parkinson's Disease, Shifting M1 to M2 Microglia Responses.Safflower Yellow regulates microglial polarization and inhibits inflammatory response in LPS-stimulated Bv2 cells.Apolipoprotein D Concentration in Human Plasma during Aging and in Parkinson's Disease: A Cross-Sectional Study.NCX1 and NCX3 as potential factors contributing to neurodegeneration and neuroinflammation in the A53T transgenic mouse model of Parkinson's Disease.The Synergy of Aging and LPS Exposure in a Mouse Model of Parkinson's Disease
P2860
Q26781130-EE110E0E-638E-4C18-BE32-FADC39381BA6Q28544818-1A218B77-7060-4A31-BEBF-52FF97791299Q33740654-D194416E-75A1-4400-86D0-743446168D77Q33924432-40126964-31E9-4E84-AAA3-405D06326F54Q34050769-0A7833F1-C79A-4B27-A5F0-F7BF1D191042Q34412996-7B7EBC28-8689-40EB-97AE-25ECCE5C5FA5Q34537231-DB39B8C7-8C35-48D4-9AB8-F465816BAF48Q34768987-19FB55ED-22BA-4FEE-B6E5-79E5FC7741E9Q34936413-86CA5F6E-F5B0-4691-9BC7-7D9F3AC6CCDAQ35039225-738B37A8-E113-4D4B-9816-128D1560A1C2Q35591414-DDCF5FD5-C28B-406E-A6C3-BFB0A654BC4BQ35657214-A95E39C3-BD46-4C2B-8C98-AFB5FF4F18A0Q35815641-D819A4BD-10F3-40B8-AEC4-1668C7F77367Q36547001-2B877D7B-1605-4E7E-BEA3-03783EF803EDQ36781712-6F20CCD5-D570-46C4-9034-83439A9F1631Q37387247-20C0C589-B2B4-49C3-BADF-760BB497776DQ38169202-202BB958-8ECA-4F98-908E-369DC459E6B4Q38541943-43F84E01-54F8-4400-8E19-351DA837C904Q38636630-0496CBB8-7AD7-45F1-95AC-81C6509DDE0CQ38674279-68909987-F6A2-46A6-A4E1-21EDB2C820B4Q38763831-D2A5778E-F2E6-464E-806C-914201F15288Q38838452-F01708C4-D054-4FAE-9C5F-21A70F5AA3EAQ38912869-51E7691C-FDB1-410B-9F6F-B56C17419E37Q39661355-755B901B-F028-41C7-9AE2-3C253AC4C56AQ41839769-A8480DB2-0A62-4A05-80E2-93DA8B2FB1B7Q43721606-253793D2-D05F-4CD5-905F-4A6AA2712D67Q46808144-4E498C1B-DB1D-42CD-A6EF-840C40804232Q47135162-13FD7E91-8FFA-4B89-9252-1191DDB77C6AQ47940102-8855A619-507B-4338-9356-E301BC529A18Q48362528-A8C5DE3B-8764-4C26-BBE4-3C8BEE4642A1Q48392503-0B31D044-A34F-4B86-B0B6-2AB6DC4130ECQ50354170-CBFB346A-D1B8-4AC6-A520-8AF5CDDABB49Q55232178-429CFFF2-3894-4F71-8B97-5B8143839611Q55512119-4482105C-65C7-4292-962E-8F4DF6C3E03BQ57051340-46B18BFD-95D8-47B6-A766-7D540014429A
P2860
Neural and immune mechanisms in the pathogenesis of Parkinson's disease.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Neural and immune mechanisms in the pathogenesis of Parkinson's disease.
@en
type
label
Neural and immune mechanisms in the pathogenesis of Parkinson's disease.
@en
prefLabel
Neural and immune mechanisms in the pathogenesis of Parkinson's disease.
@en
P1476
Neural and immune mechanisms in the pathogenesis of Parkinson's disease
@en
P2093
Fabio Blandini
P2888
P304
P356
10.1007/S11481-013-9435-Y
P577
2013-02-03T00:00:00Z
P6179
1017283274